ZIMLAB Zim Laboratories Q4 FY26 results (Jan–Mar 2026) and concall
Zim Laboratories reported a Q4 FY26 operating income of INR 105.3 crores and EBITDA of INR 13.4 crores (12.7% margin), showing sequential improvement. Full-year FY26 revenue was flat at INR 374.4 crores, impacted by INR 20-25 crores from MENA geopolitical issues. The company has completed CAPA implementation and expects a positive outcome from the recent EU GMP re-inspection, with reinstatement anticipated in the next 2-3 months. Strategic investments in R&D (8.3% of revenue) and organizational strengthening are aimed at driving future growth, particularly in NIP and OTF products, with FY27 EB
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 5.2%, net profit down 39.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 90 | 95 | 109 | 71 | 88 −1% | 108 +13% | 103 −5% |
| EBITDA | 8 | 12 | 15 | 4 | 6 −26% | 13 +6% | 7 −57% |
| Net profit | 1 | 4 | 5 | -2 | 0 −90% | 4 −2% | 3 −39% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
